COMMODORE CAPITAL LP
Q1 2026 Form 13-F

NEW YORK, NEW YORK
CIK 0001831942 · CRD 304370 · SEC-registered investment adviser
$1.7B Reported Value Total

COMMODORE CAPITAL reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $2,369,313,969, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-03-31
Reported value
$1.7B
Quarter over quarter
+21.3%
Holdings
36
Top-10 concentration
61.4%

Key People

Form ADV owners & control persons
Robert Egen Turrell Atkinson
LIMITED PARTNER
Michael Jonathan Kramarz
LIMITED PARTNER
Ameya Vikas Bapat
CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, GENERAL COUNSEL

Filing Navigation

13F Metrics

Loading 13F Metrics

Q1 2026 13F record

Q1 2026 13F filing summary

Q1 2026 Form 13F portfolio summary
Period of report March 31, 2026
Filed May 15, 2026
Form 13F-HR
Reported value $1.7B
Positions 36
Change in reported value +15.1%
New positions 13
Exited positions 10
Position turnover 50.0%
Top-10 concentration 61.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 14, 2026
33 $1.7B
Q1 2026 13F
Filed May 15, 2026
36 $1.7B
Q4 2025 13F
Filed Feb 17, 2026
33 $1.5B
Q3 2025 13F
Filed Nov 14, 2025
37 $2.0B
Q2 2025 13F
Filed Aug 14, 2025
33 $1.4B
Q1 2025 13F
Filed May 15, 2025
31 $1.4B
Q4 2024 13F
Filed Feb 14, 2025
31 $1.4B
Q3 2024 13F
Filed Nov 14, 2024
36 $1.6B
Q2 2024 13F
Filed Aug 14, 2024
35 $1.5B
Q1 2024 13F
Filed May 15, 2024
39 $1.5B
Q4 2023 13F
Filed Feb 14, 2024
32 $1.1B
Q3 2023 13F
Filed Nov 14, 2023
30 $855.5M
Q2 2023 13F
Filed Aug 14, 2023
26 $889.8M
Q1 2023 13F
Filed May 15, 2023
32 $656.8M
Q4 2022 13F
Filed Feb 14, 2023
35 $663.5M
Q3 2022 13F
Filed Nov 14, 2022
30 $621.9M
Q2 2022 13F
Filed Aug 15, 2022
24 $473.0M
Q1 2022 13F
Filed May 16, 2022
27 $447.7M
Q4 2021 13F
Filed Feb 14, 2022
25 $431.8M
Q3 2021 13F
Filed Nov 15, 2021
29 $379.3M

3 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q1 2026

Largest Q1 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 RLAY RELAY THERAPEUTICS INC $169.2M 9.79%
2 ALKS ALKERMES PLC $148.5M 8.59%
3 ELVN ENLIVEN THERAPEUTICS INC $128.4M 7.43%
4 COGT COGENT BIOSCIENCES INC $111.2M 6.43%
5 SYRE SPYRE THERAPEUTICS INC $96.5M 5.58%
6 TYRA TYRA BIOSCIENCES INC $94.8M 5.48%
7 CLDX CELLDEX THERAPEUTICS INC NEW $85.5M 4.95%
8 NUVL NUVALENT INC $85.4M 4.94%
9 AMLX AMYLYX PHARMACEUTICALS INC $78.5M 4.54%
10 KYMR KYMERA THERAPEUTICS INC $62.5M 3.61%
11 ANRO ALTO NEUROSCIENCE INC $61.2M 3.54%
12 PHVS PHARVARIS N V $54.2M 3.14%
13 ERAS ERASCA INC $51.4M 2.97%
14 GLTO DAMORA THERAPEUTICS INC $50.2M 2.91%
15 XENE XENON PHARMACEUTICALS INC $48.0M 2.78%
16 DFTX DEFINIUM THERAPEUTICS INC $37.8M 2.19%
17 LBRX LB PHARMACEUTICALS INC $37.0M 2.14%
18 EYPT EYEPOINT INC $36.4M 2.11%
19 NRIX NURIX THERAPEUTICS INC $35.3M 2.04%
20 CRVS CORVUS PHARMACEUTICALS INC $33.0M 1.91%

Values as reported on the Q1 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings